FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, particularly a method of detecting somatic mutations in the PI3K gene, which are responsible for tumour sensitivity to target therapy, using DNA biochip technology. The method includes determining presence of somatic mutations E542K, E545K, Q546K, H1047L and H1047R in the PI3K gene using LNA-blocking multiplex "nested" PCR, subsequent hybridisation of the labelled PCR product in the biochip, recording and interpreting the results.
EFFECT: invention provides rapid and efficient detection of somatic mutations in the PI3K gene, associated with tumour sensitivity to target therapy.
3 cl, 2 dwg, 4 tbl, 4 ex
